Exact Sciences Corp (EXAS) Stock Price
EXASStock
$0.00+53.14%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta0.45
EXAS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)98.22%
Price vs S&P 500 (4W)6.43%
VGM Score48.94
EXAS Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.34
3.34
3.34
3.34
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EXASExact Sciences Corp | F | B | B | $0.00 |
| NTRANatera, Inc. Common Stock | F | A | A | $336.71 |
| LHLabcorp Holdings Inc. | C | D | B | $337.68 |
| DGXQuest Diagnostics Inc. | C | D | B | $244.51 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $164.92 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | $28.01 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $76.86 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | $100.08 |
| CELCCelcuity Inc. Common Stock | — | — | D | $92.27 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $82.54 |
| VCYTVeracyte, Inc. | D | A | C | $44.04 |
About Exact Sciences Corp
Exact Sciences develops cancer screening and diagnostic tests for the United States and international markets. Its primary offerings include Cologuard, a noninvasive stool-based DNA test for colorectal cancer screening, and Oncotype DX, a precision oncology suite providing tissue-based genomic testing for cancer risk assessment and treatment guidance. The company is expanding its portfolio with OncoExTra, a liquid-based genomic profiling test, and a pipeline of blood-based solutions for cancer detection and molecular residual disease monitoring.